We find that a growing number of pharmacogenetics and pharmacogenomics products and services are now available, from drugs that target specific disease subtypes, such as ImClone Systems ...
Advances in pharmacogenetics and pharmacogenomics related to CINV should contribute to future personalized cancer therapy strategies.
Pharmacogenomics - tailoring drug treatments to individuals based on their genetics - is on the cusp of transforming drug ...
Dr. Swen is one of the primary investigators of the “Ubiquitous Pharmacogenomics” project (www.upgx.eu). U-PGx aims to implement pharmacogenetics across 7 European sites by genotyping 8,100 ...
In this webinar, Dr. Adrián Llerena from the University of Extremadura will discuss the current landscape and regulatory framework of pharmacogenetics, providing insights from leading institutions in ...
Jun J. Yang, PhD, St. Jude Departments of Pharmacy and Pharmaceutical Sciences and Oncology and first co-authors Zhenhua Li, PhD, and Satoshi Yoshimura, MD, PhD, demonstrated that treatment and ...
The FDA, which has stopped short of requiring DPYD testing for patients before receiving fluoropyrimidines, emphasized the importance of discussing it.
Advances in pharmacogenetics and pharmacogenomics related to CINV should contribute to future personalized cancer therapy strategies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback